Table 1 Characteristics of the RP patients used for qMSP
From: Epigenetic silencing of MEIS2 in prostate cancer recurrence
Variable | qMSP cohort (n = 195 PC patients) | |
|---|---|---|
Age at RP, median (range) | 64 (49–77) | |
Pre-operative PSA (ng/mL), median (range) | 13 (2.1–284.0) | |
Pathological Gleason Score | ||
< 7, n (%) | 64 (32.8) | |
= 7, n (%) | 94 (48.2) | |
3 + 4, n (%) | 86 (91.5) | |
4 + 3, n (%) | 8 (8.5) | |
> 7 n (%) | 35 (18.0) | |
Unknown, n (%) | 2 (1.0) | |
Pathological T-stage | ||
≤ pT2c, n (%) | 126 (64.6) | |
≥ pT3a, n (%) | 67 (34.4) | |
Unknown, n (%) | 2 (1.0) | |
Pathological N-stage | ||
pN0, n (%) | 167 (85.6) | |
pN1, n (%) | 15 (7.7) | |
pNX/unknown, n (%) | 13 (6.7) | |
Surgical margin status | ||
Negative margin, n (%) | 135 (69.2) | |
Positive margin, n (%) | 56 (28.7) | |
Unknown, n (%) | 4 (2.1) | |
CAPRA-S score | ||
0–2 | 54 (27.7) | |
3–5 | 77 (39.5) | |
6–10 | 50 (25.6) | |
Unknown | 14 (7.2) | |
Follow-up (months), median (range) | 131 (12–219) | |
No PSA recurrence, n (%) | 88 (45.1) | |
PSA recurrence, n (%) | 104 (53.3) | |
Unknown, n (%) | 3 (1.6) | |
Variable | AN (n = 17) | BPH (n = 6) |
Age at RP, median (range) | 65 (56–73) | 67 (56–73) |